Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 292

1.

Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options.

Merola E, Prasad V, Pascher A, Pape UF, Arsenic R, Denecke T, Fehrenbach U, Wiedenmann B, Pavel M.

Neuroendocrinology. 2019 Sep 5. doi: 10.1159/000503144. [Epub ahead of print]

PMID:
31484182
2.

FAST: A Novel, Executive Function-Based Approach to Cognitive Enhancement.

Almquist JN, Mathan S, Brem AK, Plessow F, McKanna J, Santarnecchi E, Pascual-Leone A, Cohen Kadosh R, Pavel M, Yeung N.

Front Hum Neurosci. 2019 Aug 2;13:235. doi: 10.3389/fnhum.2019.00235. eCollection 2019.

3.

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.

Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, Pavel M, Prasad V.

Eur J Nucl Med Mol Imaging. 2019 Aug 14. doi: 10.1007/s00259-019-04439-9. [Epub ahead of print]

PMID:
31414209
4.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC.

Ann Oncol. 2019 Aug 13. pii: mdz219. doi: 10.1093/annonc/mdz219. [Epub ahead of print] No abstract available.

PMID:
31407000
5.

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC.

Ann Oncol. 2019 Aug 13. pii: mdz222. doi: 10.1093/annonc/mdz222. [Epub ahead of print] No abstract available.

PMID:
31406974
6.

Tumour Growth Rate as a validated early radiological biomarker able to reflect treatment-induced changes in Neuroendocrine Tumours; the GREPONET-2 study.

Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvalho LFDP, Bezerra ROF, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Baudin E, Sundin A, Costa FP, Pavel M, Dromain C.

Clin Cancer Res. 2019 Aug 2. pii: clincanres.0963.2019. doi: 10.1158/1078-0432.CCR-19-0963. [Epub ahead of print]

PMID:
31375514
7.

Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.

Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, Maasberg S, Wiedenmann B, Pavel ME, Pascher A, Pape UF.

Endocr Relat Cancer. 2019 Jul 1. pii: ERC-18-0582.R2. doi: 10.1530/ERC-18-0582. [Epub ahead of print]

8.

Polymodal Mechanism for TWIK-Related K+ Channel Inhibition by Local Anesthetic.

Pavel MA, Chung HW, Petersen EN, Hansen SB.

Anesth Analg. 2019 May 20. doi: 10.1213/ANE.0000000000004216. [Epub ahead of print]

PMID:
31124840
9.

Exploring Associations Between the Self-Reported Values, Well-Being, and Health Behaviors of Finnish Citizens: Cross-Sectional Analysis of More Than 100,000 Web-Survey Responses.

Honka AM, Helander E, Pavel M, Jimison H, Mustonen P, Korhonen I, Ermes M.

JMIR Ment Health. 2019 Apr 22;6(4):e12170. doi: 10.2196/12170.

10.

Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.

Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Franca Bezerra RO, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Schaefer N, Sundin A, Costa F, Pavel M, Dromain C; Knowledge Network.

Oncologist. 2019 Mar 25. pii: theoncologist.2018-0672. doi: 10.1634/theoncologist.2018-0672. [Epub ahead of print]

PMID:
30910869
11.

Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.

Semrau S, Agaimy A, Pavel M, Lubgan D, Schmidt D, Cavallaro A, Golcher H, Grützmann R, Fietkau R.

J Med Case Rep. 2019 Mar 23;13(1):82. doi: 10.1186/s13256-019-1995-x.

12.

Evolution Under Normothermic Machine Perfusion of Type 2 Donation After Cardiac Death Livers Discarded as Nontransplantable.

Pavel MC, Reyner E, Molina V, Garcia R, Ruiz A, Roque R, Diaz A, Fuster J, Garcia-Valdecasas JC.

J Surg Res. 2019 Mar;235:383-394. doi: 10.1016/j.jss.2018.09.066. Epub 2018 Nov 14.

PMID:
30691820
13.

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.

Yao JC, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, Singh S, Fazio N, He W, Riester M, Patel P, Voi M, Morrissey M, Pavel ME, Kulke MH.

Endocr Relat Cancer. 2019 Apr 1;26(4):391-403. doi: 10.1530/ERC-18-0332. Epub 2019 Jan 1.

PMID:
30667365
14.

Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.

Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W.

Oncologist. 2019 Aug;24(8):e662-e670. doi: 10.1634/theoncologist.2018-0236. Epub 2019 Jan 16.

PMID:
30651397
15.

Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.

Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME; CLARINET Study Group.

BMC Cancer. 2019 Jan 14;19(1):66. doi: 10.1186/s12885-018-5257-x.

16.

Optimized imaging of the lower abdomen and pelvic region in hepatocyte-specific MRI: evaluation of a whole-abdomen first-pass shuttle protocol in patients with neuroendocrine neoplasms.

Fehrenbach U, Kahn J, Fahlenkamp U, Baur A, Pavel M, Geisel D, Denecke T.

Acta Radiol. 2019 Sep;60(9):1074-1083. doi: 10.1177/0284185118817936. Epub 2018 Dec 12. No abstract available.

PMID:
30541328
17.

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.

Pavel M, Borson-Chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D.

Cancer Chemother Pharmacol. 2019 Feb;83(2):375-385. doi: 10.1007/s00280-018-3734-1. Epub 2018 Dec 8.

PMID:
30535537
18.

A Molecular Target for an Alcohol Chain-Length Cutoff.

Chung HW, Petersen EN, Cabanos C, Murphy KR, Pavel MA, Hansen AS, Ja WW, Hansen SB.

J Mol Biol. 2019 Jan 18;431(2):196-209. doi: 10.1016/j.jmb.2018.11.028. Epub 2018 Dec 5.

19.

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.

Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH.

Clin Ther. 2018 Dec;40(12):2006-2020.e2. doi: 10.1016/j.clinthera.2018.10.008. Epub 2018 Nov 24.

20.

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators.

Oncologist. 2019 Apr;24(4):463-474. doi: 10.1634/theoncologist.2018-0217. Epub 2018 Oct 24.

PMID:
30355775
21.

Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions.

Pavel MC, Fuster J.

World J Gastroenterol. 2018 Aug 28;24(32):3626-3636. doi: 10.3748/wjg.v24.i32.3626. Review.

22.

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.

Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28.

23.

Liver transplantation from type II donation after cardiac death donor with normothermic regional perfusion and normothermic machine perfusion.

Pavel MC, Reyner E, Fuster J, Garcia-Valdecasas JC.

Cir Esp. 2018 Oct;96(8):508-513. doi: 10.1016/j.ciresp.2018.06.016. Epub 2018 Aug 6. English, Spanish.

PMID:
30093100
24.

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, Lowenthal SP, Vinik AI.

Endocr Pract. 2018 Aug 7. doi: 10.4158/EP-2018-0296. [Epub ahead of print]

PMID:
30084687
25.

Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis.

Pavel M, Renna M, Park SJ, Menzies FM, Ricketts T, Füllgrabe J, Ashkenazi A, Frake RA, Lombarte AC, Bento CF, Franze K, Rubinsztein DC.

Nat Commun. 2018 Jul 27;9(1):2961. doi: 10.1038/s41467-018-05388-x.

26.

Interplay of disorder and delocalization in photosynthetic light harvesting.

Pavel M, Rienk VG.

Curr Opin Chem Biol. 2018 Dec;47:1-6. doi: 10.1016/j.cbpa.2018.06.008. Epub 2018 Jun 26. Review.

PMID:
29957484
27.

Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study.

Pavel MC, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-Valdecasas JC.

Transplant Proc. 2018 Jun;50(5):1386-1395. doi: 10.1016/j.transproceed.2018.02.093.

PMID:
29880361
28.

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.

Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH.

Clin Ther. 2018 Jun;40(6):952-962.e2. doi: 10.1016/j.clinthera.2018.04.006. Epub 2018 May 1.

29.

A randomized trial of normothermic preservation in liver transplantation.

Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Ceresa CDL, Chiocchia V, Dutton SJ, García-Valdecasas JC, Heaton N, Imber C, Jassem W, Jochmans I, Karani J, Knight SR, Kocabayoglu P, Malagò M, Mirza D, Morris PJ, Pallan A, Paul A, Pavel M, Perera MTPR, Pirenne J, Ravikumar R, Russell L, Upponi S, Watson CJE, Weissenbacher A, Ploeg RJ, Friend PJ; Consortium for Organ Preservation in Europe.

Nature. 2018 May;557(7703):50-56. doi: 10.1038/s41586-018-0047-9. Epub 2018 Apr 18.

PMID:
29670285
30.

Modulating fluid intelligence performance through combined cognitive training and brain stimulation.

Brem AK, Almquist JN, Mansfield K, Plessow F, Sella F, Santarnecchi E, Orhan U, McKanna J, Pavel M, Mathan S, Yeung N, Pascual-Leone A, Kadosh RC; Honeywell SHARP Team authors.

Neuropsychologia. 2018 Sep;118(Pt A):107-114. doi: 10.1016/j.neuropsychologia.2018.04.008. Epub 2018 Apr 9.

PMID:
29649503
31.

IFN-α in advanced well-differentiated neuroendocrine tumors: the neglected drug?

Amoroso V, Pavel M, Claps M, Roca E, Ravanelli M, Maroldi R, Oberg K, Berruti A.

Future Oncol. 2018 Apr;14(10):897-899. doi: 10.2217/fon-2017-0667. Epub 2018 Mar 12. No abstract available.

PMID:
29528242
32.

NUCare: Advancing research on technological integration for self-management in the aging population.

Lees KE, Guthrie BJ, Henderson EL, Jimison HB, Sceppa C, Pavel M, Gordon C, Fulmer T.

Nurs Outlook. 2018 Mar - Apr;66(2):121-129. doi: 10.1016/j.outlook.2017.10.008. Epub 2017 Nov 15.

33.

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R.

Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12.

34.

Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria).

Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC.

Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.

35.

Successful treatment of high-grade pancreatic neuroendocrine neoplasms with everolimus.

Genç CG, Klümpen HJ, Denecke T, Wiedenmann B, Pavel M.

Acta Oncol. 2018 May;57(5):686-688. doi: 10.1080/0284186X.2017.1398410. Epub 2017 Nov 10. No abstract available.

PMID:
29126357
36.

Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4.

Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R.

Onco Targets Ther. 2017 Oct 16;10:5013-5030. doi: 10.2147/OTT.S142087. eCollection 2017.

37.

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB.

Clin Ther. 2017 Nov;39(11):2158-2168. doi: 10.1016/j.clinthera.2017.09.013. Epub 2017 Oct 23.

38.

Can accelerometry data improve estimates of heart rate variability from wrist pulse PPG sensors?

Kos M, Xuan Li, Khaghani-Far I, Gordon CM, Pavel M, Jimison HB.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:1587-1590. doi: 10.1109/EMBC.2017.8037141.

39.

Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.

Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC.

Cancer Sci. 2018 Jan;109(1):174-181. doi: 10.1111/cas.13427. Epub 2017 Nov 9.

40.

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC.

Lancet Oncol. 2017 Oct;18(10):1411-1422. doi: 10.1016/S1470-2045(17)30471-0. Epub 2017 Aug 30.

PMID:
28838862
41.

CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction.

Böning G, Kahn JF, Kaul D, Rotzinger R, Freyhardt P, Pavel M, Streitparth F.

Acta Radiol. 2018 May;59(5):517-526. doi: 10.1177/0284185117726101. Epub 2017 Aug 8.

PMID:
28786299
42.

Polyglutamine tracts regulate autophagy.

Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC.

Autophagy. 2017 Sep 2;13(9):1613-1614. doi: 10.1080/15548627.2017.1336278. Epub 2017 Jul 19.

43.

Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.

Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Öberg K, Leyden J.

J Glob Oncol. 2016 Jun 8;3(1):43-53. doi: 10.1200/JGO.2015.002980. eCollection 2017 Feb.

44.

Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.

Pavel ME, Chen D, He W, Cushman S, Voi M, de Vries EGE, Baudin E, Yao JC.

Pancreas. 2017 Jul;46(6):751-757. doi: 10.1097/MPA.0000000000000830.

PMID:
28609362
45.

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary.

Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N; RAD001 in Advanced Neuroendocrine Tumors, Fourth Trial (RADIANT-4) Study Group.

Neuroendocrinology. 2018;106(3):211-220. doi: 10.1159/000477585. Epub 2017 May 24.

PMID:
28554173
46.

Analysis of the long-term results of living donor liver transplantation in adults.

Sánchez Cabús S, Estalella L, Pavel M, Calatayud D, Molina V, Ferrer J, Fondevila C, Fuster J, García-Valdecasas JC.

Cir Esp. 2017 Jun - Jul;95(6):313-320. doi: 10.1016/j.ciresp.2017.03.012. Epub 2017 May 2. English, Spanish.

PMID:
28476200
47.

Simultaneous Breast and Liver Surgery in a Patient with Stage IV Triple Positive Breast Cancer - A Case Report.

Martiniuc A, Dumitraşcu T, Pavel M, Stroescu C.

Chirurgia (Bucur). 2017 Mar-Apr;112(2):165-171. doi: 10.21614/chirurgia.112.2.165.

48.

Polyglutamine tracts regulate beclin 1-dependent autophagy.

Ashkenazi A, Bento CF, Ricketts T, Vicinanza M, Siddiqi F, Pavel M, Squitieri F, Hardenberg MC, Imarisio S, Menzies FM, Rubinsztein DC.

Nature. 2017 May 4;545(7652):108-111. doi: 10.1038/nature22078. Epub 2017 Apr 26.

49.

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC.

Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193.

PMID:
28444114
50.

Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.

Rodríguez Laval V, Pavel M, Steffen IG, Baur AD, Dilz LM, Fischer C, Detjen K, Prasad V, Pascher A, Geisel D, Denecke T.

Neuroendocrinology. 2018;106(2):139-147. doi: 10.1159/000474941. Epub 2017 Apr 7.

PMID:
28384635

Supplemental Content

Support Center